HR. 1405In Committee
Enhancing Domestic Drug Manufacturing Competitiveness Act
Requires the Government Accountability Office to study regulatory barriers to domestic pharmaceutical manufacturing and report recommendations to improve U.S. competitiveness
Plain-English overview
What this bill does
Requires the Government Accountability Office to study regulatory barriers to domestic pharmaceutical manufacturing and report recommendations to improve U.S. competitiveness
Key points
- Require a GAO study
- Assess regulatory barriers
- Review supply chain impacts
- Recommend streamlining steps
Current status
Where it stands
Status
In Committee
Latest action
2025-02-18 — Referred to the House Committee on Energy and Commerce.
Related context
Topics and policy areas
undefinedAdministrative law and regulatory proceduresCongressional oversightEnvironmental regulatory proceduresGovernment studies and investigationsHealthManufacturingPrescription drugs